kras mutation and glutathion JCI Overcoming resistance to drugs targeting
Overcoming resistance to drugs targeting KRASG12C mutation kras mutation and glutathion glynac Interplays of glucose metabolism in pancreatic ductal adenocarcinoma GlyNAC Supplementation Improves Glutathione Deficiency, KRAS mutation shown to promote tumor evasion of innate immune surveillance in lung cancer Uncovering new therapeutic targets for a common KRAS mutation behind cancer KRAS targeted therapies in cancer: novel approaches and overcoming resistance BMJ Oncology
Pay in 4 interest-free payments of $7.10 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8




